Molecular Image-Guided Theranostic and Personalized Medicine 2012
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
3Department of Health Sciences, National Natural Science Foundation of China, Beijing, China
4National Institute of Radiological Sciences, Chiba, Japan
5Institute of Nuclear Energy Research, Atomic Energy Council, Taiwan
Molecular Image-Guided Theranostic and Personalized Medicine 2012
Description
Molecular image-guided therapy has demonstrated to be effective in improving diagnosis, prognosis, planning, and monitoring of personalized medication. Molecular imaging modalities include positron emission tomography (PET), single-photon emission-computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), ultrasound (US), and optical (Ramen, quantum dots, and bioluminescence). Among clinical molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target specific information as well as function, pathway activities, and cell migration in the intact organism. For instance, the radiotracer could noninvasively assess diseases treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. New leads on the development of personalized theranostic (image and treat) agents would allow more accurate in the selection of patients who may respond to treatment.
This special issue will provide a platform of efficacy of personalized medication from molecular imaging technology which will have high impact on drug discovery, delivery, and development. It will become the first issue in a series of special issues focused on molecular imaging and personalized therapy. The special issue will be of interest to translational research scientists and support staff, such as clinicians, molecular biologists, imaging scientists, pharmaceutical developers, physicists, fellows, and staffs. Both academic and clinical scientists are invited to submit the manuscripts. Potential topics include, but are not limited to:
- Image-guided theranostic approach of diseases
- Advances in bioimaging applications in preclinical drug discovery
- PET/CT and SPECT/CT in disease management
- Radiation dosimetric determination for radiotheranostic agents
- Imaging technology in drug development
- Validation of imaging agents on new molecular targets
- Personalized drug development from molecular imaging
- Nonradioactive molecular imaging probes
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jbb/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: